title: Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest.
abstract: OBJECTIVE
  To examine the conception rate after cessation of a combination of 30 microg ethinyl E2 and 2 mg dienogest (EE/DNG).
  
  
  METHODS
  Prospective observational study.
  
  
  METHODS
  Population-based cohort in Germany.
  
  
  METHODS
  Women who wished to become pregnant after cessation of an oral contraceptive (EE/DNG).
  
  
  METHODS
  None.
  
  
  METHODS
  Cumulative conception rate within 1 year after termination of EE/DNG and time to pregnancy.
  
  
  RESULTS
  After 1 year of follow-up, the cumulative pregnancy rate was 86.6% (full analysis set; n = 706). When all participants with complete data were analyzed (n = 652), the cumulative pregnancy rate was 94.0%. More than 15% of the patients conceived in each of the first three cycles after termination of EE/DNG; the mean time to pregnancy was 3.5 cycles. The preceding duration of treatment with EE/DNG did not influence the conception rate. Except in the youngest age group (16-18 years), a certain delay was observed in the other age groups.
  
  
  CONCLUSIONS
  The present prospective study revealed only a slight delay in regaining fertility during the first three cycles after cessation of EE/DNG. Thereafter, the cumulative rate of conception did not differ from that observed in fertile women who attempted to become pregnant without prior contraception.
authors.affiliation: Department of Obstetrics and Gynecology, J. W. Goethe University, Frankfurt am Main, Germany.
authors.forename: Inka
authors.initials: I
authors.lastname: Wiegratz
authors.forename: Katrin
authors.initials: K
authors.lastname: Mittmann
authors.forename: Horst
authors.initials: H
authors.lastname: Dietrich
authors.forename: Thomas
authors.initials: T
authors.lastname: Zimmermann
authors.forename: Herbert
authors.initials: H
authors.lastname: Kuhl
mesh_terms: D000328:Adult; D017677:Age Distribution; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens / Q000008:administration & dosage; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D005298:Fertility / Q000187:drug effects*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017063:Outcome Assessment, Health Care; D011247:Pregnancy; D018873:Pregnancy Rate; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D028761:Withholding Treatment / Q000706:statistics & numerical data*
chemical_list: D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D004997:Ethinyl Estradiol; C023635:dienogest; D009277:Nandrolone